Daiichi Sankyo launches malignant glioma treatment Delytact in Japan

Written by Ruchika Sharma Published On 2021-11-06T09:00:31+05:30 | Updated On 6 Nov 2021 9:00 AM IST

Daiichi Sankyo launches malignant glioma treatment Delytact in Japan

Tokyo: Daiichi Sankyo Company, Limited has recently announced that the company has launched DELYTACT (teserpaturev/G47∆)*1, an oncolytic virus developed by the company in collaboration with Professor Tomoki Todo (hereinafter, Dr. Todo) of the Institute of Medical Science, The University of Tokyo.

DELYTACT received conditional and time-limited marketing approval in Japan as a regenerative medical product for treatment of malignant glioma in June 2021 based on results from a Japanese phase 2 clinical trial (investigator-initiated trial) in patients with glioblastoma* (a type of malignant glioma*) conducted by Dr. Todo.

For the time being, DELYTACT will be commercially available only at hospitals that served as trial sites. Daiichi Sankyo will establish a stable supply system of the medicine as soon as possible.

Daiichi Sankyo to offer DELYTACT as a new option for the treatment of malignant glioma and to contribute to the high unmet medical needs of patients suffering from this brain cancer.

DELYTACT (teserpaturev/G47∆) is a genetically engineered oncolytic herpes simplex virus type 1 (HSV-1) developed by Dr. Todo and his colleagues. DELYTACT has triple mutations within the viral genome that cause augmented and selective replication in cancer cells (third generation oncolytic HSV-1).

Glioblastoma is highly malignant glioma (grade IV) and found in approximately 60% to 70% of patients with malignant glioma.

Read also: Daiichi Sankyo names Ken Takeshita as Global Head of RnD

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751